GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QSAM Biosciences Inc (OTCPK:QSAM) » Definitions » Financial Strength

QSAM Biosciences (QSAM Biosciences) Financial Strength : 7 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is QSAM Biosciences Financial Strength?

QSAM Biosciences has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

QSAM Biosciences did not have earnings to cover the interest expense. As of today, QSAM Biosciences's Altman Z-Score is 0.00.


Competitive Comparison of QSAM Biosciences's Financial Strength

For the Biotechnology subindustry, QSAM Biosciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QSAM Biosciences's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QSAM Biosciences's Financial Strength distribution charts can be found below:

* The bar in red indicates where QSAM Biosciences's Financial Strength falls into.



QSAM Biosciences Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

QSAM Biosciences's Interest Expense for the months ended in Dec. 2023 was $0.05 Mil. Its Operating Income for the months ended in Dec. 2023 was $-0.48 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

QSAM Biosciences's Interest Coverage for the quarter that ended in Dec. 2023 is

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

QSAM Biosciences's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.008 + 0) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

QSAM Biosciences has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


QSAM Biosciences  (OTCPK:QSAM) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

QSAM Biosciences has the Financial Strength Rank of 7.


QSAM Biosciences Financial Strength Related Terms

Thank you for viewing the detailed overview of QSAM Biosciences's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


QSAM Biosciences (QSAM Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
9442 Capital of Texas Highway North, Plaza 1, Suite 500, Austin, TX, USA, 78759
QSAM Biosciences Inc is a clinical-stage novel radiopharmaceutical company. The company is developing treatments for bone cancer and related diseases.
Executives
Adam King officer: Chief Financial Officer 9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759
Link Jr. Charles J director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Adriann Sax director 7 DORSET COURT,, EAST BRUNSWICK, NJ 08816
David Charles Link director 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Douglas R Baum director, officer: CEO & Director 5000 RAFFEE COVE, AUSTIN TX 78731-1132
C Richard Piazza director, officer: Executive Chairman 2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3
Checkmate Strategic Capital Holdings, Llc other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Strategic Capital 2, Llc 10 percent owner, other: See Explanation of Responses 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Capital Group, Llc 10 percent owner, other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Charles Thomas Paschall other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Christopher M. Nelson director, officer: General Counsel 420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480
Scott W. Whitney director, other: Former Director 96 WINDSOR DRIVE, PINE BROOK NJ 07058
Kevin Bolin director, officer: Former Chairman & CEO 1081 ROSEDALE DRIVE, ATLANTA GA 30306
Tristan Peitz director, other: Former Director C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480
Joel David Mayersohn director 350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301

QSAM Biosciences (QSAM Biosciences) Headlines

From GuruFocus